RHYTHM PHARMACEUTICALS, INC. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Pamela Cramer's separation (effective July 1, 2026) yields 39 weeks severance at $455,500 annual base salary (~$346k), 9 months health benefits, 24,300 vesting performance units, plus advisory role through Nov 16, 2026. Non-Employee Director Compensation Program (effective June 24, 2026) establishes $50k base retainer plus committee fees ($6k–$35k), initial director grants of $1M equity (50/50 options/RSUs), annual grants of $500k. Two financing amendments to HCR revenue-interest facility: (1) March 27, 2024 amendment allows omission of non-US lockbox/sweep accounts in UK, Canada, Netherlands; (2) June 29, 2026 amendment permits $21M aggregate Series A preferred dividends from June 30, 2026 onward.
Why this rating
Severance (~$0.35M) and director compensation are routine corporate housekeeping relative to $3.8B market cap. Financing amendments reflect operational flexibility, not debt restructuring or impairment.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.